Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple-antibiotic therapy for symptomatic Blastocystis infection
ACTRN12611000918921Phase 3Completed
- Sponsor
- The University of Queensland
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trimethoprim + sulfamethoxazole, diloxanide and secnidazole in Blastocystis hominis infection, sponsored by The University of Queensland. Primary endpoint: Clearance of Blastocystis from stool specimen. Started Aug 2011; status: completed.
02
Drugs
trimethoprim + sulfamethoxazolediloxanidesecnidazole
03
Conditions
Blastocystis hominis infection
Beyond the preview
Go deeper on ACTRN12611000918921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000918921.